PDCD1 and Miyoshi myopathy: In order to monitor the metastatic power of melanoma cells after exposure to circulating EVs isolated from i) NRES (before or after anti-PD1 treatment); ii) long RES (pre-therapy and after a prolonged response) and iii) RES > PRO (pre-therapy, when they responded and at progression), we evaluated the ability of all circulating EVs in modulating the invasive behaviour of four MM cell lines, BRAFV600 mutant: Hmel-1 (red) and Hmel-9 (black) and BRAF wt: LND-1 (red) and MGS (black).